Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (late spermatids) | 0.10 |
| chemistry Open Targets | compounds already reach it: fingolimod hydrochloride, amiselimod hydrochloride, fingolimod lauryl sulfate +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 593 | 0.76 |
| pathways Reactome | 2 pathways; mostly lysosome and autophagy | 1.00 |
No case: the score is under the bar. Receipt 14702
Sealed predictions
- S1PR2 in dopamine neurons, braak+0.07 (p 0.849) → -0.29 (p 0.449)receipt 14739
Swarm cases
receipt 14739: S1PR2 in dopamine neurons, braak
- power
- full sample -0.21 (p 0.413, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.27 (p 0.285, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.29 (p 0.250, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.11, sign flips 0; without severely affected donors -0.21 (p 0.413, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for S1PR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts